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Dobutamine and Hydralazine: Comparative Influences of Positive
Inotropy and Vasodilation on Coronary Blood Flow and Myocardial
Energetics in Nonischemic Congestive Heart Failure
RAYMOND D. MAGORIEN, MD, DONALD V. UNVERFERTH, MD, FACC,
GREGORY P. BROWN, MD, CARL V. LEIER, MD, FACC
Columbus, OhIO
Coronary blood flow and myocardial energetics were
assessed after the administration of a parenteral inotrope
(dobutamine hydrochloride) and an oral vasodilator agent
(hydralazine) in 10 patients with nonischemic congestive
heart failure. Dobutamine (5 ltg/kg per min) and hy-
dralazine (1 mg/kg) when group-matched elicited an
identical increase in cardiac index and stroke volume
index. Both agents augmented coronary blood flowwhile
reducing coronary vascular resistance. Both forms of
therapy elicited a significant increase in myocardial ox-
ygen consumption. Dobutamine, demonstrating a bal-
anced effect on the coronary circulation, induced a pro-
portional increase in coronary blood flow and myocardial
Dobutamine and hydralazine are two frequently utilized agents
in the treatment of congestive heart failure, Dobutamine, a
synthetic catecholamine with beta.sadrenergic receptor ag-
onist activity, is a potent myocardial inotropic agent (1-3).
Hydralazine induces arteriolar relaxation with peripheral cir-
culatory vasodilation and reduction in systemic vascular
resistance and ventricular filling pressure (4-6), In the set-
ting of congestive heart failure, both drugs have well doc-
umented salutary central hemodynamic effects with aug-
mentation of cardiac output and reduction in ventricular
filling pressure (7-12).
Nonischemic congestive cardiomyopathy is associated
with diminished coronary blood flow per unit myocardial
muscle mass and evidence of relative hypoperfusion of left
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oxygen consumption, with the arterial-venous oxygen
difference across the coronary vascular bed remaining
unchanged. Hydralazine enhanced the myocardial ox-
ygen supply versus demand ratio; despite a significant
increase in myocardial oxygen consumption, the arterial-
venous oxygen difference and the myocardial extraction
ratio diminished. Both forms of therapy enhanced car-
diac performance without inducing any electrocardio-
graphic or clinical evidence of ischemia.
Dobutamine, a positive inotropic agent, elicited a bal-
anced effect on the coronary circulation while hydral-
azine, a vasodilator agent, induced a greater increase in
coronary flow than in myocardial oxygen demand.
ventricular subendocardium (13-16). Any agent that poten-
tially augments myocardial oxygen consumption (inotrope)
or diminishes the coronary perfusion pressure (vasodilator)
may unfavorably alter the tenuous balance between oxygen
demand and supply and induce myocardial ischemia. These
deleterious effects might theoretically be mitigated by con-
comitant vasodilator- or inotrope-induced reduction in left
ventricular wall stress secondary to decreased chamber size
or increased coronary blood flow. This study was therefore
designed to assess the effects of dobutamine and hydralazine
on the coronary circulation and myocardial energetics in
patients with chronic nonischemic congestive heart failure.
Methods
Study patients. Ten patients withcongestive heart failure (New
York Heart Association functional classes III and IV) were eval-
uated. Five women and five men with a mean age of 48 years
(range 25 to 58) underwent cardiac catheterization and coronary
angiography that documented nonischemic congestive cardiomy-
opathy. The left ventricular ejection fraction was less than 30%
in all patients while eight demonstrated a left ventricular filling
pressure greater than 20 mm Hg. The group had been maintained
on conventional cardiac medications mcludmg digitalis. diuretics
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Table I. Effects of Dobutamine and Hydralazine on Central Hemodynamic Measurements
HR (bea ts/nu n) AP (rnrn Hg) PCW (mm Hg) CI (Iucr v nu n pcr 1112 )
Case C D5 H DIO C D5 H DIO C D5 H DIO C D5 H DIO
68 68 80 78 90 97 89 108 21 22 20 25 2.0 2 I 26 2 I
2 108 107 104 95 74 64 64 66 27 21 26 19 20 3 0 2. 1 3.6
3 88 98 93 11 5 84 85 81 78 28 30 30 32 28 4.0 3 I 4.2
4 96 108 102 11 4 95 91 89 90 26 22 23 16 2 I 30 25 3 I
5 82 80 95 100 100 97 67 95 15 15 10 12 27 3.0 5.2 4.7
6 117 120 114 125 87 78 70 78 32 26 28 26 2. 1 3.4 3.5 4.8
7 72 72 72 105 93 86 80 93 8 8 7 9 32 3.4 32 52
8 96 106 90 108 80 84 80 89 23 19 17 15 1.6 2.8 2.3 3.0
9 82 87 81 94 78 63 65 65 26 13 15 13 23 3.9 3.3 4.3
10 84 92 100 103 103 106 92 102 26 24 20 19 2 I 26 3.0 34
Mean 89 94 93 104t 88 85 78t 86 23 20' 20t 19* 2.3 3. 1+ 3 It 38+
SD ± 15.2 ± 15 8 ± 12.6 ± 12.9 ± 9.5 ± 10. 1 ±9.5 ± 14.2 ± 6.9 ± 9.8 ± 7.6 ± 73 ±0.3 ± 0.6 ± 0.9 ±0.9
p (D5 vs H) NS 0.01 NS NS
' p < 005 . "p < 0 0 1. +p < 000 1 (ver-uv control)
AP = mean systemic blood pressure. C = control. CI = cardiac Index. 05 = dobutarnme 51lg. 01 0 = dobutarnme 10 Ilg. H = hydralazrne. HR = heart rate. l VSWI
and nitrates. Forty-eight hours before the onset of study. diuretics
and nitrates were discontinu ed . Exclusio n criteria includ ed primary
valvular heart disease , active myocardm s, uremia. primary hepatic
dysfunction. anemia and pregnancy.
Protocol a nd procedures. Written infor med consent was ob-
tained fro m eac h pati ent. Before the contro l period . a thin-walled .
arterial cannula was placed in the radial artery for continuous
monitor ing of systemic artenal pressure and to provide a port for
arterial blood samples . A balloon-t ipped triple-lumen thcrrnod i-
lut ron ca theter was placed in the pulmonary artery for monitoring
centra l hemodynamic van ables. The coronary sinus was cannu-
lated under fluoroscopic control utilizing a dual tberrrustor coronary
sinus catheter. Catheter positi on and stability during the study
period were confirmed by contrast angiography and temperature
assessment according to the techniques descnbed by Ganz c t a!'
( 17).
In the supine resting state , central hemodynamic variables 111-
eluded pulm onary arte ry . pulmonary capillary wedge and systemic
artena l pressure utilizing techniques previously reported by this
laboratory (6) . Cardiac output (thermod ilution technique 11 81l was
measured in triplicate with less than 10% variation using an in-
strumentation Laboratories 60 I computer and 602 recorder. Cor-
onary sinus blood flow measurement s (thermodilution technique
[17]) were performed with a 7 French model CCS- 7U-90B dua l
thermistor coronary SIOU S catheter interphased with a WIlton Web-
ster CBA -2 10 two-chann el Wheatstone bndge with self-contained
Table 2. Effects of Dobutamine and Hydralazine on Coro nary Blood Flow and Myoca rdial Energet ics
CSF CSF/CO x 100 AP - pew CYR
(ml/min) (o/c flow ) (mm Hg) (111 m IIg/ml per 111m)
Case C D5 H DIO C D5 H DIO C D5 H DIO C D5 H DIO
I 59 55 79 80 1.6 1.5 1.8 1.8 69 75 69 83 1.17 1.36 0.87 1 04
2 200 202 290 224 62 4 3 8.9 3.8 47 43 38 47 024 02 1 o 13 02 1
3 188 294 208 278 4.0 4.6 4.2 4.2 56 55 51 46 0.30 0.19 0.24 0.16
4 183 357 337 319 5.0 7.1 8.1 6.1 69 69 66 74 0.38 0.20 0.19 0.20
5 186 307 286 255 4.5 6.6 36 3.6 85 82 57 83 OA6 0.27 020 0.32
6 136 173 284 193 4 0 3.0 5.0 2.4 55 52 42 52 0 40 0.30 0.15 0 27
7 130 142 121 243 2.0 2.2 2.0 2.6 85 78 73 84 065 055 060 035
8 70 104 114 215 1.7 1.6 2.0 29 57 65 63 74 0.81 0.62 0.55 0.34
9 195 213 319 221 4.6 3.0 SA 2.8 52 50 50 52 027 0.23 o 16 023
10 97 122 147 143 1.9 2.0 2.1 I 8 77 82 72 83 079 067 049 058
Mean 144 197* 218t 217+ 3.5 3.6 4.3' 3.2 65 65 58* 68 055 046* 036+ 0.37';'
SD ± 54 ± 97 ± 96 ± 68 ± 1 6 ± 2 0 ± 2.6 ± 1.3 ± 13.8 ± 14 3 ± 125 ± 16 5 ± O30 ±O 37 ± O25 ±O 26
p (D5 vs H) NS NS 0.05 NS
' p < 0 05. t p < 0 0 1. +p < 000 1 (vcrvus control)
(A - eS) 0 , = arterial-coronary vinus oxygen difference. AP - pew = mean systemic blood pres- urc minus pulmonary wedge difference. C = control. CSF =
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Table 1. (continued)
SVI (rnl/rn/) SYR (dynes-s-cm -5) LVSWI (g-m/nr')
Case C D5 H DIO C D5 H DIO C D5 H DIO
I 30 31 33 27 2011 2120 1580 2316 28 32 31 30
2 19 28 20 38 1838 1087 1635 923 12 16 10 24
3 32 41 33 36 1480 1072 1368 937 24 31 25 22
4 22 28 25 27 2147 1456 1767 1398 21 26 25 27
5 33 38 54 47 1942 1680 635 1070 38 42 42 53
6 17 29 31 39 2047 1093 912 778 12 20 18 28
7 44 48 45 49 1283 1103 1155 791 48 51 48 56
8 17 26 26 28 1616 1007 1178 992 13 23 24 28
9 28 45 40 46 1489 720 884 671 20 31 27 32
10 25 28 30 33 1622 1372 1019 1026 26 31 29 37
Mean 27 34* 34* 37t 1747 1271t 1213t 1090+ 24 30'c 28t 34:::
SD ±85 ±98 ± 10.1 ±8.2 ±288 ±398 ±367 ±474 ± 11.7 ± 10.1 ± 10.7 ± 11.7
p(D5 vs H) NS NS NS
= left ventncular stroke work index. NS = not srgruficant, p = probabihty, PCW = mean pulmonary capillary wedge. SD = standard deviation. SVI = stroke volume
index. SVR = systemic vascular resistance
solid state preamplifiers (17,19). A multichannel Electronics for
Medicine recorder transcribed simultaneous thermistor signals.
Oxygen content was measured by the electrochemical technique
(Lex-Oy-Con,Lexington Instruments). A calibrated infusion pump
(Harvard Apparatus) was utihzed to provide intravenous dobuta-
mine hydrochloride delivery. Coronary flow measurements and
central hemodynamic variables were monitored during a 4 hour
control period to ensure the stability of baseline data. Any patient
displaying a coefficient of variation greater than 10% during the
control period was excluded from the study.
After the control period. intravenous dobutamine hydrochlonde
infusion was instituted at 5 ILg/kg per min (stage I), 10 ILg/kg per
min (stage II), a reequilibration control period (stage Ill) and then
oral hydralazine, I mg/kg (stage IV). Measurementsduring stages
I and II were made after a IS minute equilibration period, stage
III at a return to baseline levels and stage IV readings determined
every 60 minutes over the ensuing 4 hours after oral hydralazine.
Central hemodynamic calculations (20) included cardiac index,
stroke volume index, systemic vascular resistance and left ven-
tricular stroke work index. Coronary hemodynamicand myocardial
metabolic calculations included coronary SInUS flow, coronary vas-
cular resistance and myocardial oxygen consumption, using for-
mulas previously reported by our laboratory (21).
Statistical analysis. Mean values and standard deviation were
determined during control periods, dobutamine infusion (5 and 10
ILgikg per min) and hydralazine therapy (I mg/kg). Control values
Table 2. (continued)
(A - CS) O2 Oz MVOz
(ml/hter) (% extracnon) (mJimm)
Case C D5 H DIO C D5 H DIO C OS H DIO
I 114 117 108 116 70 72 67 72 7 6 9 9
2 119 115 114 III 78 75 74 72 24 23 36 25
3 75 70 77 77 60 57 62 63 14 21 16 21
4 105 106 93 106 71 72 64 72 19 24 31 34
5 86 86 58 85 68 70 46 72 16 26 16 22
6 116 118 88 117 84 86 63 86 16 24 25 21
7 95 101 96 80 61 65 62 52 12 14 13 19
8 103 102 95 102 72 72 65 72 7 10 II 22
9 85 77 72 80 64 58 54 60 17 18 23 27
10 141 147 143 130 80 82 80 72 14 18 21 19
Mean 104 104 94* 100 71 71 64* 69 15 18" 20t 21t
SD ± 19.6 ±22.4 ±23.7 ± 18.6 ±7.9 ±9.2 ±9.5 ±8.8 ±5.1 ±6.6 ±8.5 ±6.0
p(D5 vs H) 005 0.05 NS
coronary smus blood flow; CSF/CO x 100 = percent coronary circulation: CVR = coronary vascular resistance. D5 = dobutamme 5jJ.g; DIO = dobutamme 10jJ.g. H =
hydralazine. MVOz = myocardial oxygen consumption. NS = not srgmficanr, 0, (% extraction) = myocardial extraction ratio. p = probability. SD = standard devranon
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represent the mean of the dctcrminanons made dunng the predrug
control period andrepeated during the second equilibration control
period. Hydralazine values represent the average of the 2 and 3
hour responses. The Student's t test for paired and unpaired anal-
ysis was used to compare data when appropriate. A probability
value of p < 0.05 was established to indicate Significant change.
(Fig. 2A). The ratio of percent change of coronary flow to
cardiac output remained constant with dobutamine (5 ILg/
kg per min) but increased significantly with hydralazine
(Fig. 2B). Both agents elicited a significant increase in myo-
cardial oxygen consumption (Fig. 3). Concomitant with the
elevation of myocardial oxygen consumption, the arterial-
venous oxygen difference and the percent myocardial ox-
Figure I. Systemic and coronary Circulatory vascular responsesat baseline
control (C) (and repeat control [CD and after adrrumstranonof dobutamme
(D) (5 iLg/kg per nun) and hydralazme (H) (I mg/kg) therapy. Panel A,
Dobutammeand hydralazine improvedcentral hemodynamicvanables with
a well matched increase in cardiac index (Cl) and decrease m systemic
vascular resistance (SYR) Panel B, Both agents markedly diminished
coronary vascular resistance (CYR) With a concomitant mcrease incoronary
blood flow (CSF). P = probability; SEM = standard error of the mean;
X = mean.
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Results
Effects on hemodynamics. The central hemodynamic
profile of this group is presented in Table I. Before drug
treatment, baseline cardiac index was depressed (2.3 ± 0.3
liters/min per rrr'), pulmonary capillary wedge pressure el-
evated (23 ± 6.9 mm Hg) and systemic vascular resistance
increased (1747 ± 288 dyness-cm r "); all findings were
commensurate with the diagnosis of moderate congestive
cardiac failure. With low dose dobutamine infusion (5 ILg/
kg per min), heart rate and mean arterial pressure did not
significantly change; however, systemic vascular resistance
and pulmonary capillary wedge pressure decreased With a
concomitant increase in cardiac index, stroke volume index
and left ventricular stroke work index. Hydralazine (I mg/
kg) induced no appreciable change in heart rate but did
diminish mean arterial pressure and systemic vascular re-
sistance with reciprocal augmentation of cardiac index, stroke
volume index and left ventricular stroke work index. In-
creases in cardiac index and stroke volume index were iden-
tically group-matched with low dose dobutamine and hy-
dralazine. In this population, high dose dobutamine (10 ILg/
kg per min) elicited a significant increase in heart rate when
compared with control, low dose dobutamine and hydral-
azine. The increase in cardiac index significantly exceeded
that noted with low dose dobutamine and hydralazine; how-
ever, because of heart rate changes, there was no significant
difference in stroke volume index when comparing the three
modes of treatment. Dobutamine (10 ILg/kg per min) mark-
edly diminished systemic vascular resistance while left ven-
tricular stroke work index was increased over both control
and hydralazine therapy.
Effects of intravenous dobutamine and oral hydral-
azine on coronary blood flow and myocardial energetics
(Table 2). Dobutamine in both dose ranges had no effect
on the mean systemic blood pressure-pulmonary wedge
pressure difference (a formulated estimate of coronary per-
fusion pressure), whereas hydralazine diminished the cor-
onary vascular pressure gradient. At matched doses. both
agents decreased coronary vascular resistance and aug-
mented coronary blood flow, similar to the changes noted
in the systemic vascular bed (Fig. IA and B). Before drug
treatment, 3.5% of cardiac output was distributed to the
coronary circulation. After dobutamine (5 ILg/kg per min)
infusion, the relative flow distribution remained unaltered;
however with hydralazine therapy, 4.3% of total cardiac
output was directed into the coronary vascular circulation
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Discussion
In the setting of congestive heart failure, the known sal-
utary central hemodynamic effects of both dobutamine and
hydralazine are well documented. However. the relative
effects of these agents on coronary blood flow and myo-
cardial energetics remain dependent on their ability to main-
tain an appropriate balance between myocardial oxygen de-
mand and supply (2 1-25) . Studies in both animal models
and patients strongly suggest that cardiac hypertrophy ad-
versely affects the coronary circulation with enhanced vul-
nerability of subendocardial muscle to ischemiaand necrosis
(14- 16,26 ,27) . Our patients with nonischemic cardiomy-
opathy demonstrated diminished coronary blood flow per
unit mass of myocardium (40 ± 12 mill 00 left ventri-
cle-min) . Previous studies with the inotropic agents digoxin
and amrinone have demonstrated diminution of myocardial
oxygen consumption with concomitant augmentation of car-
diac output in patients with significant heart failure (28,29) .
Other investigators have speculated on the potential ability
of vasodilator therapy to improve cardiac performance at a
lower level of oxygen consumption than required by ino-
tropic therapy (30-32) . Dobutamine (5 p.g/kg per min) and
hydralazine (1 mg/kg) therefore were matched to induce an
equal increase in cardiac index (35%) while central and
coronary hemodynamic variables were measured to compare
dobutamine infusion was accompanied by a 20% increase
in myocardial oxygen consumption and a 37% increase in
coronary blood flow. After hydralazine administration.
myocardial oxygen consumption increased by 33% with a
concomitant 51% augmentation of coronary blood fl ow.
Figure 2. Mean ratio of coronary versus systemic blood flow at base line
and after administration of dobut amme (5 /-Lg/kg per min) and hydralazine
( I 109/kg). Panel A, The percent card iac output (CO) directed to the
coronary circulation (CSF) following drug therapy Pan el B, Dobutamme
imtia ted a balanced effect on the coronary circulation. while hydralazine
augmented the relative flow to the coronary vascu lar bed. Abbreviation,
as before.
ygen extraction remained constant with low and high dose
dobutamine infusion. Despite the increase in total myo-
cardial oxygen consumption with hydralazine, the arterial-
venous oxygen difference narrowed and the percent myo-
cardial oxygen extraction diminished (Fig. 3). Low dose
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Figure 3. Mean mdexe-, of myocardial
energetl~s . Myocardial ox ygen co nsump-
tion (MVOl) Increased with both agents
With dobutamine (5 /-Lg/kg pcr min). the
arte riovenous coronary smus oxyg en (j A.
CS jOl) diffe rence and percent oxygen
extraction remained unaltered while hy-
dralazine dimin ished these variable, de-
spite an overall increase In myocardial
oxygen consumption. Abbre vian ons a,
before
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o
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the relative effect on myocardial oxygen consumption and
coronary supply.
Effects on myocardial oxygen demand and coronary
blood flow. Heart rate, myocardial wall stress and con-
tractility constitute the three major determinants of myo-
cardial oxygen demand (33-35). Heart rate remained sta-
tistically unchanged with both agents. Myocardial wall stress
was not directly assessed; however, the modest reduction
in both left ventricular filling pressure and mean systemic
pressure is consistent with an actual decrease in wall stress .
Contractility, the third major myocardial oxygen consump-
tion determinant, has been clearly shown to increase with
dobutamine infusion in both normal hearts and heart failure
models (1,3). The inotropic state of the ventricle was not
directly measured in this study; however, the noted increase
in stroke volume index at a diminished filling pressure would
suggest that dobutamine did in fact augment myocardial
contractility . Recent studies by our group have also dem-
onstrated positive inotropic properties with hydralazine (36)
and prominent coronary vascular effects (21) which may,
in tum , account for the comparable increase in myocardial
oxygen consumption noted with both the inotropic (dobu-
tamine) and vasodilator (hydralazine) agents.
Coronary bloodfiow was greatly enhanced. and coronary
vascular resistance significantly diminished with both agents.
Hydralazine, however, demonstrated a more pronounced
effect on the coronary vascular bed than on the systemic
circulation while dobutamine initiated a more balanced cir-
culatory response. Coronary perfusion pressure remained
unaltered with dobutamine but decreased with hydralazine
administration. The marked attenuation of coronary vascular
resistance with hydralazine adequately compensated for the
reduction in perfusion pressure and resulted in a significantly
increased myocardial blood supply. Before pharmacologic
manipulation, 3.5% of cardiac output was directed to the
coronary vascular bed. The distribution of coronary blood
flow remained unchanged with dobutamine , but after hy-
dralazine, the balance shifted toward the myocardium with
coronary flow then accounting for 4.3% of total cardiac
output.
Balance between increased myocardial oxygen de-
mand and augmented coronary blood flow. In this group
of patients with moderately severe congestive heart failure,
both inotropic and vasodilator intervention , group-matched
to elicit a similar increase in cardiac performance, aug-
mented myocardial oxygen demand. After dobutamine (5
IJ-g/kg per min), the increased myocardial oxygen con-
sumption was balanced by augmented coronary flow with
the arteriovenous oxygen difference and myocardial oxygen
extraction ratio remaining unaltered. High dose dobutamine
resulted in further enhancement of central and coronary
circulatory hemodynamic variables (increased cardiac out-
put and coronary blood flow, decreased systemic and cor-
onary vascular resistance) while myocardial oxygen con-
sumption increased modestly and the arteriovenous difference
across the coronary vascular bed remained unchanged . With
hydralazine administration, the arteriovenous oxygen dif-
ference and myocardial extraction ratio actually decreased,
suggesting that the enhanced coronary flow (increased pro-
portion of total cardiac output) more than compensated for
the increase in myocardial oxygen consumption .
Regional myocardial perfusion was not measured in this
study and, therefore , one cannot exclude the possibility of
relative subendocardial hypoperfusion or arteriovenous mi-
crocirculatory shunting in this group of patients with in-
creased left ventricular muscle mass. However, the overall
marked improvement in global left ventricular function (in-
creased stroke volume index at decreased left ventricular
filling pressure) without any clinical or electrocardiographic
evidence of ischemia would suggest the maintenance of a
favorable balance between myocardial supply and demand.
Our data must be interpreted in the strict context of the
patient group studied. The response of the coronary circu-
lation may vary considerably in patients without elevated
muscle mass and ventricular filling pressures and in patients
with ischemic cardiomyopathy and fixed atherosclerotic
lesions.
Implications. Both the inotropic and vasodilator agents
enhanced the central hemodynamic function of this patient
population with nonischemic congestive cardiomyopathy.
Despite a marked reduction in both left ventricular filling
pressures and systemic vascular resistance with no increase
in heart rate or systemic blood pressure (no significant in-
crease in rate-pressure product), both agents increased myo-
cardial oxygen demand. Vasodilator therapy, at a paired
level of cardiac performance. did not diminish myocardial
oxygen consumption when compared with inotropic inter-
vention. However, the hydralazine-induced shift in total
cardiac output toward the coronary vasculature plus the greater
increase in coronary flow than in myocardial oxygen con-
sumption (55 versus 33%, p < 0.05) suggest a more fa-
vorable balanced oxygen supply and demand . In a group of
patients with attenuated myocardial flow per unit mass and
diminished subendocardial perfusion, these coronary hemo-
dynamic changes may, in part , account for the acute aug-
mentation of global myocardial performance after hydral-
azine therapy.
We thank Max Bacher for her technical assistance
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